Combination Therapy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel for Metastatic Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Resistance and EGFR Mutations.

The EGFR L858R mutation showed a favorable trend in overall survival compared with the EGFR Ex19del mutation (not evaluated vs. 23.6 months).

also in 661 other papers

In a post-hoc analysis conducted by Reck et al., an encouraging trend toward prolonged median OS was observed (NE vs. 17.5 months, HR = 0.39 (95% CI, 0.14-1.07)), alongside a statistically significant improvement in median PFS (9.7 vs. 6.1 months, HR = 0.42 (95% CI, 0.22-0.80)) when comparing ABCP with BCP.

also in 141 other papers